TERN241220P6000
- 0.20
- 0.000.00%
Terns Pharmaceuticals Newsroom
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $14
Mizuho Securities Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
Oppenheimer Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Terns Pharmaceuticals(TERN.US) With Hold Rating, Maintains Target Price $7.5
Hold Rating on Terns Pharmaceuticals' TERN-701 Due to Uncertain Efficacy Despite Promising Safety Profile
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $7.5 Price Target
Terns Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Terns Pharmaceuticals Price Target Raised to $20.00/Share From $17.00 by Oppenheimer
Terns Pharma Analyst Ratings
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
TD Cowen Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
Terns Pharma Analyst Ratings
BMO Capital Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright Maintains Terns Pharmaceuticals(TERN.US) With Hold Rating, Raises Target Price to $7.5
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
Terns Pharmaceuticals: Promising Oncology Developments and Strategic Pipeline Diversification Justify Buy Rating
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating